Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Toxicol Sci ; 34 Suppl 1: SP147-55, 2009.
Article in English | MEDLINE | ID: mdl-19265281

ABSTRACT

To investigate the optimal administration period for evaluating ovarian toxicity that reflects abnormal female fertility in the repeated dose toxicity study, atrazine, a potent herbicide with endocrine-disrupting activity, was administered to female Sprague-Dawley (Slc:SD) rats for two or four weeks at doses of 3, 30 or 300 mg/kg for the repeated dose toxicity study, and at doses of 3, 30 or 100 mg/kg for the female fertility study from two weeks before mating to Day 7 of gestation. In the two-week repeated dose toxicity study, prolongation of diestrus and histopathological findings such as loss of the currently formed corpora lutea, decrease in the numbers of previously formed corpora lutea, increase in large-sized atretic follicles, and swelling of the previously formed luteal cells were observed in the 300 mg/kg group, suggesting that atrazine had an anovulatory effect through suppression of the luteinizing hormone surge. In the female fertility study, copulation failure caused by prolongation of diestrus was observed in one animal in the 100 mg/kg group, which could be due to the anovulatory effect of atrazine. It is demonstrated that the effect of atrazine on female fertility can be assessed by detailed histopathological examination of ovaries in a two-week repeated dose toxicity study, provided the appropriate dose levels are selected.


Subject(s)
Atrazine/toxicity , Fertility/drug effects , Herbicides/toxicity , Ovary/drug effects , Toxicity Tests/methods , Animals , Atrazine/administration & dosage , Body Weight/drug effects , Copulation/drug effects , Corpus Luteum/drug effects , Corpus Luteum/metabolism , Corpus Luteum/pathology , Drug Administration Schedule , Estrous Cycle/drug effects , Female , Herbicides/administration & dosage , Japan , Male , Organ Size/drug effects , Ovarian Follicle/drug effects , Ovarian Follicle/metabolism , Ovarian Follicle/pathology , Ovary/pathology , Ovary/physiopathology , Pregnancy , Proliferating Cell Nuclear Antigen/metabolism , Public-Private Sector Partnerships , Rats , Rats, Sprague-Dawley , Societies, Scientific , Weight Gain/drug effects
2.
J Pharmacol Toxicol Methods ; 58(1): 11-26, 2008.
Article in English | MEDLINE | ID: mdl-18593646

ABSTRACT

INTRODUCTION: The murine local lymph node assay (LLNA) is a well-established alternative to the guinea pig maximization test (GPMT) or Buehler test (BT) for the assessment of the skin sensitizing ability of drugs and chemicals. Daicel Chemical Industries Ltd. has developed a modified LLNA based on the adenosine triphosphate (ATP) content (LLNA-DA). We conducted 2 interlaboratory validation studies to evaluate the reliability and relevance of LLNA-DA. METHODS: The experiment involved 17 laboratories, wherein 14 chemicals were examined under blinded conditions. In the first study, 3 chemicals were examined in 10 laboratories and the remaining 9 were examined in 3 laboratories. In the second study, 1 chemical was examined in 7 laboratories and the remaining 4 chemicals were examined in 4 laboratories. The data were expressed as the ATP content for each chemical-treated group, and the stimulation index (SI) for each chemical-treated group was determined as the increase in the ATP content relative to the concurrent vehicle control group. An SI of 3 was set as the cut-off value for exhibiting skin sensitization activity. RESULTS: The results of the first study obtained in the experiments conducted for the 3 chemicals that were examined in all the 10 laboratories and for 5 of the remaining 9 chemicals were sufficiently consistent with small variations in their SI values. The sensitivity, specificity, and accuracy of LLNA-DA against those of GPMT/BT were 7/8 (87.5%), 3/3 (100%), and 10/11 (90.9%), respectively. In the second study, all the 5 chemicals studied demonstrated acceptably small interlaboratory variations. DISCUSSION: In the first study, a large variation was observed for 2 chemicals; in the second study, this variation was small. It was attributed to the application of dimethylsulfoxide as the solvent for the metallic salts. In conclusion, these 2 studies provide good evidence for the reliability of the LLNA-DA.


Subject(s)
Dermatitis, Allergic Contact/etiology , Irritants/toxicity , Local Lymph Node Assay , Adenosine Triphosphate/metabolism , Animals , Dermatitis, Allergic Contact/diagnosis , Female , Mice , Mice, Inbred CBA , Reproducibility of Results , Solvents/chemistry , Toxicity Tests/methods
3.
J Neurochem ; 80(6): 989-97, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11953449

ABSTRACT

We previously described that recombinant interleukin-1beta (IL-1beta) induced the significant release of substance P (SP) via a cyclooxygenase (COX) pathway in primary cultured rat dorsal root ganglion (DRG) cells. In the present study, we examined the involvement of two types of phospholipase A2 (PLA2) enzymes, which lie upstream of COX in the prostanoid-generating pathway, in the IL-1beta-induced release of SP from DRG cells. The expression of type IIA secretory PLA2 (sPLA2 -IIA) mRNA was undetectable by ribonuclease protection assay in non-treated DRG cells, while in DRG cells incubated with 1 ng/mL of IL-1beta, the expression was induced in a time-dependent manner. On the other hand, type IV cytosolic PLA2 (cPLA2 ) mRNA was constitutively expressed in the non-treated DRG cells, and treatment with 1 ng/mL of IL-1beta for 3 h significantly increased the levels of cPLA2 mRNA. The IL-1beta-induced SP release was significantly inhibited by the sPLA2 inhibitor, thioetheramide phosphorylcholine (TEA-PC), and the cPLA2 inhibitor, arachidonyl trifluoromethyl ketone (AACOCF3 ). Furthermore AACOCF3 suppressed the induction of sPLA2 -IIA mRNA expression induced by IL-1beta. These observations suggested that two types of PLA2, sPLA2 -IIA and cPLA2, were involved in the IL-1beta-induced release of SP from DRG cells, and that the functional cross-talk between the two enzymes might help to control their activity in the prostanoid-generating system in DRG cells. These events might be key steps in the inflammation-induced hyperactivity in primary afferent neurons of spinal cord.


Subject(s)
Interleukin-1/pharmacology , Neurons, Afferent/drug effects , Neurons, Afferent/metabolism , Phospholipases A/metabolism , Substance P/metabolism , Animals , Cells, Cultured , Enzyme Induction/drug effects , Enzyme Inhibitors/pharmacology , Ganglia, Spinal/cytology , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Gene Expression/drug effects , Group II Phospholipases A2 , Group IV Phospholipases A2 , Isoenzymes/antagonists & inhibitors , Isoenzymes/genetics , Isoenzymes/metabolism , Male , Neurons, Afferent/cytology , Phospholipases A/antagonists & inhibitors , Phospholipases A/genetics , Phospholipases A2 , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...